Cytonics founder Dr. Guy Scuderi explains A2M using a Venus flytrap. Cartilage-degrading enzymes take the molecule’s “bait,” become trapped inside its cage-like structure and are neutralized before being cleared by the body. That natural defense is the science behind CYT-108. Learn more and invest before the current offering closes July 30: invest.cytonics.com REG CF Disclaimer: In making an investment decision, investors must rely on their own examination of the issuer and the terms of the offering, including the merits and risks involved. Cytonics has filed a Form C with the Securities and Exchange Commission in connection with its offering, a copy of which may be obtained here: rb.gy/24a8ut